Outcomes after hematopoietic stem-cell transplantation for hematologic malignancies in patients with or without advance care planning

被引:33
|
作者
Ganti, Apar Kishor [1 ]
Lee, Stephanie J.
Vose, Julie M.
Devetten, Marcel P.
Bociek, R. Gregory
Armitage, James O.
Bierman, Philip J.
Maness, Lori J.
Reed, Elizabeth C.
Loberiza, Fausto R., Jr.
机构
[1] Univ Nebraska Med Ctr, Hematol Oncol Sect, Dept Internal Med, Omaha, NE 68198 USA
关键词
D O I
10.1200/JCO.2007.11.1914
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Engagement in advance care planning (ACP) is viewed as a way to prepare for possible death. In patients undergoing hematopoietic stem-cell transplantation (HSCT), an aggressive but possibly curative procedure for cancer, encouraging engagement in ACP is difficult. We conducted this analysis to determine if engagement in ACP among patients who undergo HSCT is associated with adverse outcomes. Patients and Methods Adult patients who were undergoing their first HSCT for hematologic malignancies between 2001 and 2003 were included. ACP was defined as having a living will, a power of attorney for health care, or life-support instructions. Outcomes assessed included the length of hospital stay, in-hospital mortality, and overall survival. Results Of the 343 patients, 172 did not have ACP, whereas 171 did have ACP, and 127 of those were reviewable. Of those with reviewable ACP, 28 patients (22%) completed ACP before cancer diagnosis, 87 (68%) completed ACP after the cancer diagnosis but before HSCT, and 12 (10%) engaged in ACP after HSCT. Patients without ACP before HSCT had a significantly greater risk of death compared with patients with ACP (hazard ratio, 2.11; 95% CI, 1.34 to 3.33; P = .001) while adjusting for statistically significant factors. Conclusion Our study demonstrated that lack of engagement in ACP is associated with adverse outcomes after HSCT. Thus, the patients least likely to have planned for poor outcomes are the ones most likely to face them. Additional studies should evaluate the nature of this association and should seek modifiable explanatory factors that could be the target of interventions.
引用
下载
收藏
页码:5643 / 5648
页数:6
相关论文
共 50 条
  • [41] Nontuberculous mycobacterial infections in patients with hematologic malignancies and recipients of hematopoietic stem cell transplantation
    El Zein, Said
    Mendoza, Maria A.
    Wilson, John W.
    TRANSPLANT INFECTIOUS DISEASE, 2023, 25
  • [42] Clinicopathologic Characteristics Of Secondary Malignancies In Survivors Of Allogeneic Hematopoietic Stem Cell Transplantation In Patients With Hematologic Malignancies
    Chaulagain, Chakra P.
    Kaul, Esha
    Pilichowska, Monika
    Klein, Andreas K.
    Sprague, Kellie
    Miller, Kenneth B.
    BLOOD, 2013, 122 (21)
  • [43] Functional Status Is Associated with Outcomes after Allogeneic Stem Cell Transplantation for Older Patients with Hematologic Malignancies
    Huang, Li-Wen
    Huang, Chiung-Yu
    Andreadis, Charalambos
    Logan, Aaron C.
    Mannis, Gabriel N.
    Smith, Catherine C.
    Gaensler, Karin M.
    Martin, Thomas G., III
    Damon, Lloyd E.
    Steinman, Michael A.
    Olin, Rebecca L.
    BLOOD, 2018, 132
  • [44] Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation
    Mielcarek, Marco
    Storer, Barry E.
    Flowers, Mary E. D.
    Storb, Rainer
    Sandmaier, Brenda M.
    Martin, Paul J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (10) : 1160 - 1168
  • [45] Total marrow irradiation in hematopoietic stem cell transplantation for hematologic malignancies
    Kerbauy, Mariana Nassif
    Arcuri, Leonardo Javier
    Favareto, Sergio Leonardo
    de Rezende, Ana Carolina Pires
    Hamerschlak, Nelson
    FRONTIERS IN MEDICINE, 2023, 10
  • [46] The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantation
    Limengmeng Wang
    Haowen Xiao
    Xing Zhang
    Chong Wang
    He Huang
    Journal of Hematology & Oncology, 7
  • [47] The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantation
    Wang, Limengmeng
    Xiao, Haowen
    Zhang, Xing
    Wang, Chong
    Huang, He
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2014, 7
  • [48] Clinical Significance of microRNAs in Hematologic Malignancies and Hematopoietic Stem Cell Transplantation
    Sevcikova, Aneta
    Fridrichova, Ivana
    Nikolaieva, Nataliia
    Kalinkova, Lenka
    Omelka, Radoslav
    Martiniakova, Monika
    Ciernikova, Sona
    CANCERS, 2023, 15 (09)
  • [49] Ethical and Analytic Challenges With Genomic Sequencing of Relapsed Hematologic Malignancies Following Allogeneic Hematopoietic Stem-Cell Transplantation
    Marwa, Bilal
    Krueger, Joerg
    Stephenson, Elizabeth A.
    Davidson, Scott
    Allan, David
    Knoppers, Bartha
    Zawati, Ma'n
    Sullivan, Patrick
    Shlien, Adam
    Malkin, David
    Fernandez, Conrad, V
    Villani, Anita
    JCO PRECISION ONCOLOGY, 2021, 5 : 1339 - 1347
  • [50] HLA-haploidentical related hematopoietic stem cell transplantation and mesenchymal stem cell transplantation in patients with hematologic malignancies.
    Zhang, Xiaoyan
    Li, Jianyong
    Cao, Kejiang
    Wu, Hanxin
    Lu, Hua
    Qian, Sixuan
    Xu, Wei
    Liu, Peng
    Meng, Lijuan
    Zhu, Yu
    BLOOD, 2006, 108 (11) : 446B - 446B